Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: A clinical review

BackgroundMonotherapy with nanoparticle albumin-bound (nab)-paclitaxel has demonstrated improved efficacy and safety compared with solvent-based paclitaxel and docetaxel.DesignA comprehensive review of all reported studies of nab-paclitaxel combinations with other agents in all breast cancer settings was undertaken.ResultsMost studies reviewed are small, phase II and non-comparative. Combinations studied included nab-paclitaxel plus trastuzumab and/or bevacizumab (with or without additional cytotoxic agents), gemcitabine, capecitabine, carboplatin, or lapatinib. The majority of metastatic and neoadjuvant studies demonstrated satisfactory efficacy and safety for nab-paclitaxel combinations, although conclusions regarding comparison with solvent-based taxane (SBT) regimens are not possible. The two adjuvant studies confirmed the safety of nab-paclitaxel combinations in this setting.ConclusionsAlthough results of this review indicate that nab-paclitaxel may be an appropriate substitute for SBTs in combination regimens, additional research is required to confirm the place and cost effectiveness of these combinations before nab-paclitaxel could be recommended routinely in all settings.